Optimi Reports Q2 2026 Financial Results
Second quarter revenue growth driven by expanded GMP psilocybin shipments and DEL-amended product mix.
PRINCETON, BC — Optimi Health Corp. (CSE: OPTI · OTCQX: OPTHF) today reported financial results for the three months ended March 31, 2026.
Key highlights:
- Revenue of $3.1M, up 42% year-over-year - Gross margin of 54% (vs 48% Q2 2025) - Cash position of $8.4M
Financial statements and MD&A are available on the Company's SEDAR+ profile.